We are proud to be supporting a Biotechnology start-up based in Cambridge who are taking an innovative approach to cancer medicines through the targeting of disease specific macrophages. This is an incredible opportunity to make a substantial positive impact on healthcare.
We are assisting this organisation in their search for a Senior/Principal Bioinformatician. The successful candidate will be able to perform multi-omics data analysis to support the company’s drug discovery programs and lead development of custom computations tools, supporting the target identification and validation platform. Working closely with the biology and drug discovery teams, you will work on a range of disease indications including cancer. As the first member of the bioinformatics team, you will be instrumental in establishing the company’s cloud-based infrastructure.
- – Inform target selection and validation through design of novel computational approaches using human multi-omics data.
- – Be responsible for the development of bioinformatic and statistical analysis pipelines to integrate various genomic, proteomic, transcriptomic, biochemical, imagine and other datasets.
- – Manage implementation of computational infrastructure to the cloud and/or in-house server systems.
- – Using systems biology approaches, build an in silico knowledgebase of critical targets, signalling pathways and diseases.
You must have the following experience:
- – PhD in Computational Biology Bioinformatics or related discipline with 3 years of experience in drug discovery.
- – Experienced with analysis, integration, and QC of high dimensional multi-omics datasets (Genomics, proteomics, transcriptomics) related to disease research.
- – Experienced with a variety of statistical methods, prediction models and machine learning algorithms used in biological/medical research.
- – Proficiency in one or more programming language (e.g. R, Python).
- – Proficient with cloud computing (e.g. AWS).
It would be beneficial if you had prior experience working in drug discovery on target identification/biomarker discovery.